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ABSTRACT
Emerging multidrug-resistant tuberculosis (MDR/XDR-TB) has become a major public
health problem, placing millions at risk. Further, nosocomial transmission of MDR/XDR-TB
places both patients and healthcare workers at an even higher risk. Effective tuberculosis (TB)
infection prevention and control (IPC) policies in high-risk settings must use evidence-based
science and should be customized to the setting. However, the growing incidence of
MDR/XDR-TB in some global settings raises questions about whether adequate healthcarerelated TB IPC policies are in place and whether they are implemented effectively. The purpose
of this systematic literature review was to catalogue healthcare-related TB IPC policy research
conducted in high-prevalence settings and draw a picture of existing evidence-based TB IPC
policies and their implementation, with a focus on preventing and controlling nosocomial
transmission of MDR/XDR-TB.
Two databases (PubMed and Embase) were searched from 1990 – 2013 and outputs were
categorized by region/country, income, MDR/XDR-TB incidence, level of IC intervention, and
time period. None of the 20 captured research studies were conducted in TB high-prevalence,
low-income settings. Most (12/20) were implemented within the Pan American Health
Organization region, followed by the African (4/20) and European (4, 20%) regions. Most
studies reviewed (70%) were undertaken because of an outbreak and most (70%) were published
between 1990 – 2000.
This systematic literature review showed a gap in research on TB IPC policies addressing
nosocomial transmission of MDR/XDR-TB in high-prevalence, low-income settings. TB IPC

policy development and implementation should be routinely undertaken as a part of effective and
efficient public health practice. Development of TB IPC global best practices should be
guaranteed and a concerted effort to promote, distribute, train, and implement these TB IPC best
practices in low-resource countries would help mitigate the growing incidence of MDR/XDR-TB
worldwide.
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CHAPTER I: INTRODUCTION
1.1.

Overview
Despite globally adopted strategies to control tuberculosis (TB) and globally declining

incidence and mortality rates of the disease over the years, it remains a major public health
problem (WHO, 2012). TB was included by Stop TB Partnership in the Millennium
Development Goals (MDG 6) to be achieved by 191 UN Member States by the year 2015 (STOP
TB Partnership, 2010; United Nations, 2013). The TB epidemic is complicated by the multidrugresistant/extensively drug-resistant tuberculosis (MDR/XDR-TB) which is a man-made disease
and emerged as a result of inadequate TB treatment. It is defined as “caused by organisms that
are resistant to isoniazid and rifampicin (MDR-TB); and by organisms that are resistant to
isoniazid and rifampicin as well as any fluoroquinolone and any of the second–line anti-TB
injectable drugs (amikacin, kanamycin or capreomycin)” (WHO, 2013b). Once developed, drugresistant strains of TB can be transmitted directly from person to person as drug-sensitive TB.
Treatment of drug-resistant TB is expensive, long-term (18-24 months), and complex requiring
daily injections and involving serious side effects.
Globally MDR-TB is reported in 3.7 % of new TB cases and in 20% of previously treated
TB, though these figures vary substantially from country to country (WHO, 2013b). Extensively
drug-resistant TB comprises about 9% of MDR-TB cases and has been reported in at least 84
countries by March 2013. About 0.5 million new MDR-TB cases were estimated by WHO
globally in 2011 with approximately 60% occurring in Brazil, Russian Federation, India, China
and South Africa. There were 27 high MDR-TB burden countries (MDR-HBCs) estimated by
WHO in 2008, defined as having had “at least 4000 MDR-TB cases occurring annually and/or at
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least 10% of newly registered TB cases with MDR-TB”. The highest proportions of MDR-TB
among TB cases, however, are in the Eastern European and Central Asian countries. High-cost
diagnosis and long treatment of drug-resistant TB put economic burden on health systems,
governments and other payers globally. It is estimated that two billion USD will be required in
2015 to diagnose and treat MDR-TB (WHO, 2013b). Concerning is the fact that speed of
MDR/XDR-TB propagation is much higher than slowly emerging treatment programs with less
than 10% of the estimated cases with drug-resistant TB being treated (WHO, 2010).
Another challenge in addressing drug-resistant TB is its interplay with HIV. People living
with HIV (PLHIV) and infected with TB have 20 times greater risk of developing active TB than
HIV-negative persons (WHO, 2013a). Out of 1.4 million people who died from TB in 2012,
430,000 deaths were among PLHIV (WHO, 2012). There is evidence of significantly higher
mortality rate and short survival associated with drug-resistant TB outbreaks among PLHIV.

2.2. Nosocomial Transmission
Inadequate TB treatment regimens leading to the lower levels of success and the higher
rates of default or failure have long been considered driving factors for drug-resistant TB.
However, over time, dynamics of factors responsible for drug-resistant TB have changed with
about 40% of MDR-TB patients having a history of defaulted or failed treatment, and about 30%
of them as new cases without previous treatment history (Figure 1)(WHO, 2011). Furthermore,
recent studies show even higher proportions (about 50%) of new MDR-TB cases among people
who never been treated for TB before, demonstrating direct transmission of drug-resistant strains
(IOM, 2011). In addition, patients, who were previously treated for TB, acquire drug-resistant
tuberculosis through transmission rather than as a consequence of non-adherence to the previous
treatment. When transmission happens in healthcare setting it is considered as nosocomial.
5

Figure 1. Distribution of MDR-TB Cases by History of Previous Treatment (Source: WHO,
2011).

European CDC (2008) defines nosocomial infections or “healthcare-associated
infections” (HCAI) as “infections acquired during a stay in a healthcare setting which were
neither present nor incubating at the time of admission in a healthcare setting …including
occupational infections among staff of healthcare facilities”. Nosocomial (healthcare-associated)
transmission of drug-resistant TB has been documented in many countries including
industrialized and has become a growing public health concern. It became one of the major
contributing factors to MDR-TB and more recently the XDR-TB epidemic which threatens
achievements in TB control and elimination globally (WHO, 2009). Numerous outbreaks of
nosocomial transmitted drug-resistant TB since 1990s have been associated with limitedresource settings, high prevalence of HIV and lack of infection control policies, indicating a need
for further and systematic examination of effective TB control strategies (Frieden TR, Sherman
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L, Maw K, & et al, 1996); (Edlin et al., 1992); (Gandhi et al., 2013). The Center for Global
Development has emphasized the following causes of drug-resistant TB: health system factors,
including infection control; drug technology; and behavioral factors (Beith, 2008) (Figure 3).

Figure 2. Factors that Drive Drug-resistance (adopted from CGD, 2008).
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Some populations are of increased risk to nosocomial transmission of drug-resistant TB
such as patients with HIV infection and healthcare workers. HIV-positive status is related to
higher risk of exposure to MDR-TB patients, due to increased hospitalizations in healthcare
settings with inadequate infection control (WHO, 2010). Nosocomial transmission among
healthcare workers (HCWs) is of particular concern because of the documented increase in rates
of TB in this population: higher attributable risk of TB in this group compared to the general
population (ranged from 25 to 5,361 per 100,000 per year), high prevalence of TB (on average
54% (range 33% to 79%)), and increased risk of developing latent tuberculosis (from 0.5% to
14.3%) (Joshi, Reingold, Menzies, & Pai, 2006). HCWs are a valuable and often scarce
resource, and their safety and protection from preventable TB exposure, morbidity and mortality
should become an essential part of the IPC programs (WHO/CDC, 1999).

1.3.TB IPC
Rising demand from countries for guidance on TB transmission prevention and their need
to understand policy gaps in TB IPC led to the development of TB IPC by WHO in 2009. The
document defined TB IPC as “a combination of measures aimed at minimizing the risk of TB
transmission within populations...[founded on] early and rapid diagnosis and management of TB
patients” and included evidence-based recommendations on TB infection control in healthcare
facilities, congregate settings and households (WHO, 2009). According to WHO (2009), there is
evidence that implementation of IPC measures, including administrative and environmental
controls and personal protection, reduces transmission of TB in healthcare facilities (Table 1).
Important contributing factors of nosocomial transmission as delayed diagnosis, unrecognized
multi-drug resistance, inadequate isolation and infection control practices, poor ventilation and
air circulation, are addressed in the WHO document.
8

Table 1. Set of measures for healthcare facility-level TB infection control (WHO, 2009)
Facility-level measures
1.

Implement the set of facility level managerial activities:
a) Identify and strengthen local coordinating bodies for TB infection control, and
develop a facility plan (including human resources, and policies and procedures to
ensure proper implementation of the controls listed below) for implementation.
b) Rethink the use of available spaces and consider renovation of existing facilities or
construction of new ones to organize implementation of controls.
c) Conduct on-site surveillance of TB disease among health workers and asses the
facility.
d) Address advocacy, communication and social mobilization (ACSM) for health
workers, patients and visitors.
e) Monitor and evaluate the set of TB infection control measures.
f) Participate in research efforts.

Administrative controls
2.

3.

Promptly identify people with TB symptoms (triage), separate infectious patients, control
the spread of pathogens (cough etiquette and respiratory hygiene) and minimize time spent
in healthcare facilities.
Provide a package of prevention and care interventions for health workers, including HIV
prevention, antiretroviral therapy and isoniazid preventive therapy (IPT) for HIV-positive
health workers.

Environmental controls
4.
5.

Use ventilation systems.
Use ultraviolet germicidal irradiation (UVGI) fixtures, at least when adequate ventilation
cannot be achieved.

Personal protective equipment
6.

Use particulate respirators

Importantly, TB IPC was neglected for many years and has been recognized as a priority
issue that should be incorporated into country-level policy. A majority of countries (66% of 199)
reported having a policy on TB IPC, yet none of them had provided information on
implementation of TB IPC measures (WHO, 2009). In 2011, less than half (41%) of the 27
MDR-HBCs reported having the national infection control plan (WHO, 2011).
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1.4. Gap and Purpose of the Study
The growing global incidence of MDR/XDR-TB raises questions about whether adequate
healthcare-related TB IPC policies are in place and whether they are implemented effectively.
Continuing outbreaks of drug-resistant TB with recent high fatality XDR-TB highlight pitfalls in
the progress of TB IPC implementation to reduce transmission of MDR and XDR TB in high
HIV and TB burden countries (Gandhi et al., 2013). Many questions related to TB IPC and their
implementation in high-burden and low-income countries, still have to be answered to be able to
effectively address nosocomial transmission of drug-resistant TB: what works effectively and
what is feasible in certain settings in terms of resources and policies; what are the barriers for
development and adequate implementation of TB IPC; what are the gaps and variables that are
not understood or taken into consideration in implementing TB IPC policies? WHO has
recognized MDR-TB as one of “the greatest areas of unmet need for TB research”, highlighting
urgent need to scale up research as to provide evidence to countries to reach MDG and STOP TB
Partnership goals (WHO, 2011).
Effective TB ICP in high-risk settings must use evidence-based science and should be
customized to the setting. Synthesis of the current knowledge base and its distribution globally
and in particular in the low-income MDR-HBCs might bring more understanding to the current
challenges in control of drug-resistant TB. However, there have been a small number of
published literature reviews on TB IPC and nosocomial transmission of MDR/XDR-TB. In
addition, those reviews have number of limitations: available literature rarely gives global
overview and many times analyses only one or some of the TB IPC measures, which provides a
fragmented picture of TB IPC. Most importantly, methodology of the traditional literature review
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carries more potential biases during selection and analysis and provides less reliable basis for
decision making in comparison to the systematic review.
The purpose of this systematic literature review was to catalogue healthcare-related TB
ICP policy research conducted in high-prevalence settings and draw a picture of existing
evidence-based TB ICP policies and their implementation, with a focus on preventing and
controlling nosocomial transmission of MDR/XDR-TB. Studies will be categorized by region
(WHO regions), time period (1990-2000, 2001-2013), country income level (World Bank), level
of intervention (WHO TB IPC levels), and study settings, involvement of HIV infection and
outbreaks. The landscape of the published TB IC research related to nosocomial drug-resistant
TB may contribute to an understanding of the global distribution of the knowledge base and
existing gaps. It may also inform policy makers on research and resource allocation for research
according to the needs and resources of the regions and countries.
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CHAPTER II. REVIEW OF THE LITERATURE
2.1. Nosocomial transmission
Nosocomial transmission and re-infection by MDR/XDR-TB in congregate settings has
been investigated and documented in numerous studies as an on-going factor contributing to the
drug-resistant TB epidemic worldwide, especially in co-variance with HIV. A recent
observational study, exploring hospital-associated epidemiologic links in XDR- TB outbreak in
South Africa identified nosocomial transmission links for 82% of patients (Gandhi et al., 2013).
Almost all of the patients (93%) were hospitalized while infectious (duration M =5 days;
interquartile range: 10–25 days). The study reported multiple generations of nosocomial
transmission due to a high degree of interconnectedness which was facilitated by poor infection
control measures, high HIV prevalence and delayed diagnosis. These findings have been
supported by a number of other studies in different countries establishing nosocomial
transmission of drug-resistant TB due to inadequate infection control measures, delayed
diagnosis, exacerbated by HIV infection among patients and healthcare workers (Fischl et al.,
1992; Nodieva et al., 2010; Ritacco et al., 1997). Sissolak et al. (2010) has demonstrated that
undetected cases contribute substantially to the MDR/XDR-TB pandemic due to the same
factors, especially in high HIV-burden settings, emphasizing inadequate infection control
measures and potentially infectious status of those patients during their hospitalization (Sissolak,
Bamford, & Mehtar, 2010). Another study in Japan confirms ongoing community transmission
of MDR/XDR- TB and underlines an urgent need to improve of infection control, including an
isolation policy for patients with drug-resistant TB (Murase et al., 2010). DNA fingerprinting
analysis of MDR/XDR-TB strains isolated from TB patients all over Japan in 2002 showed 38%
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of the strains arranged into 9 clusters with geographic links. Moreover, there was a significant
association found between the XDR-TB strains and clustering in comparison to non-XDR MDR
strains (71% vs. 24%; p = 0.003), highlighting that transmission plays a critical role in the new
incidence of XDR TB.

2.2. TB IPC, by levels of infection control
A systematic review was conducted to inform development of WHO TB IPC policy and
indicated substantial gaps in knowledge of effectiveness and efficacy of TB IPC measures
(WHO, 2009). General findings and policy recommendations for TB IPC were elaborated by the
document; however, it didn’t focus on IPC related to drug-resistant tuberculosis. Importantly, the
critical need to scale up TB IPC research has been highlighted in the document. All TB IC
recommendations in the document have specific notes on the level of recommendation and
quality of evidence supporting it: almost all of them were indicated as strong recommendations
with low-quality evidence. In addition to the conventional TB IPC measures the WHO policy
document paid special attention to some new factors, such as selective administrative controls
(minimize time spent in health-care facilities), design of buildings, provision of HCWs with HIV
prevention and treatment package. Finally, integration of IPC efforts with other health-system
work, monitoring and evaluation of TB IPC and involvement of civil society on all stages of
infection control programs, were recommended.
According to WHO (2009), TB IPC policy with the goal to minimize the risk of
nosocomial transmission of TB, should be a part of the national infection prevention and control
policies (WHO, 2009). Managers on national, subnational and health facility levels are
recommended to be directed by the developed set of four -level hierarchy infection controls with
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administrative level as the most effective and the least expensive, followed by environmental and
respiratory controls.
2.2.1. Facility-level control

Importance of the facility-level control, which includes on-site surveillance of TB among
HCWs and assessment of the facility, was brought lately by increasing incidence of TB among
this population. Nosocomial TB in HCWs is suggested as “the special issue” with median
annual incidence 5.8% (range 0%-11%) in low- income and 1.1% (range, 0.2%-12%) in highincome countries (Shenoi, Escombe, & Friedland, 2010). Since IPC practices largely depend on
HCWs, more behavioral research among this population is recommended by the authors. Higher
risk for skin test conversion (25% vs 12.7%) among medical students on clinical training was
associated with the smaller rooms, fewer windows and ineffective mechanical ventilation
systems of healthcare settings in Lima, Peru (Nardell & Dharmadhikari, 2010). A study from
South Africa demonstrated that HCWs in high HIV burden area were significantly more likely to
be hospitalized with either MDR-TB or XDR-TB than were non-health care workers (O'Donnell
et al., 2010). Incidence of MDR-TB hospitalization was estimated as 64.8 per 100,000 HCWs
versus 11.9 per 100,000 non-HCWs (incidence rate ratio, 5.46 [95% CI, 4.75 to 6.28]). Incidence
rate ratio of XDR-TB hospitalizations among HCWs versus non-HCWs was estimated as 6.69
[CI, 4.38 to 10.20]). HCWs with MDR-TB or XDR-TB were more likely to be female (78% vs.
47%; P < 0.001) and less likely to report previous tuberculosis treatment (41% vs. 92%; P <
0.001). High occupational risk of exposure and contracting drug-resistant TB emphasizes
importance of regular surveillance on TB among HCWs and critical need for effective TB IPC
programs.
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2.2.2. Administrative level controls

Administrative level TB IPC measures aim to prevent generation of infectious droplets
nuclei with M. tuberculosis and consequently reducing exposure of patients and HCWs to the
infection (WHO/CDC, 1999). This level includes triage and isolation of infectious patients,
control of the spread of M. tuberculosis through respiratory hygiene and cough etiquette, and
reduction of time spent in hospital. Role of administrative IC level increases substantially when
it comes to MDR-TB, which is associated with longer time of infectiousness compared to drug
susceptible TB (Andrews, Shah, Gandhi, Moll, & Friedland, 2007). Administrative controls, in
particular rapid diagnoses, are suggested as the most effective and least expensive interventions
(Nardell & Dharmadhikari, 2010). Simple triage (based on acid-fast bacilli stain (AFB) for TB
and rapid HIV test) and separation strategy from Haiti were demonstrated as a good practice of
administrative controls that could be tailored to resource-limited settings.
Administrative controls should also ensure provision of prevention and care interventions
for HCWs including HIV prevention, isoniazid preventive therapy (IPT) and antiretroviral
therapy for HIV-positive HCWs (WHO, 2009). HIV- infection along with other factors as
delayed diagnosis of tuberculosis and poor infection control has been proven to increase the risk
of transmission of multidrug-resistant strains of TB (Gandhi et al., 2013; Laing, Ocampo, &
Harris, 2010). O’Donnell et al. compared and found in the study in South Africa differences in
HIV infection between HCWs and non-HCWs as not significant (55% vs. 57%), although
comparison of HCWs to HIV-infected patients on antiretroviral therapy (ART) was significant
and showed HCWs as being more likely to receive ART (63% vs. 47%; P < 0.001) (O'Donnell et
al., 2010).
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2.2.3. Environmental level controls

Over-crowded wards in resource-limited, high-burden settings are indicated as one of the
main barriers to effective implementation of TB transmission control. Thus environmental
controls are proposed to start with renovation or construction of buildings (Nardell &
Dharmadhikari, 2010). Natural ventilation is also recommended in low-resource settings in a
warm climate considering minimal hourly ventilation rates issued by WHO. It is recommended
as a low cost, low maintenance and the most effective (when design of the building includes
considerations for it) airborne infection control measure (Shenoi et al., 2010). Mechanical
ventilation and mixed-mode systems in addition to natural ventilation are proposed by Nardell et
al. (2010) when the latter does not sufficiently meet WHO standards.
Germicidal ultraviolet air disinfection could be a low-cost complementary system to the
natural and mechanical ventilation, in particular an upper room ultraviolet germicidal irradiation
(UVGI), which is highlighted as a highly effective disinfection mean (70-80%). UVGI addresses
limitation of natural ventilation, being climate independent, and in addition of relatively low cost
(Shenoi et al., 2010).Yet, UVGI has its certain limitations requiring proper installation that
depends on availability of skilled engineers, architects, and good quality and lower cost UVGI
fixtures (Nardell & Dharmadhikari, 2010).
2.2.4. Respiratory level controls

WHO (2009) recommends particulate respirators for use by HCWs when caring for
infectious or suspected in being infectious patients. For patients surgical masks are
recommended to reduce spread of pathogens. Respiratory protection is acknowledged as a
complementary level of protection for HCWs after other strategies have been implemented, and
recommendations made to elaborate low-cost, non-disposable, of better appearance respirators
16

allowing verbal communication with the patients (Nardell & Dharmadhikari, 2010). Respirators
N95 and FFFP2 have been indicated as certified and the most widely used respirators in US and
Europe respectively. Shenoi et al. argues that even though respirators N95 were recommended as
a personal protection, however, no discussion of the costs and availability of this type of
protection were provided (Shenoi et al., 2010). A comprehensive training program for HCWs on
correct and routine use of particulate respirators was recommended by WHO (2009), however,
some studies report that fit-testing program is neglected (Nardell & Dharmadhikari, 2010). Fittesting for correct size and compliance to routine use of respirators were indicated as challenges
to be addressed in personal protection.

2.3. Implementation and compliance to the TB ICP policy
Literature suggests that despite availability of TB IPC policies and some of the measures
implemented, compliance to those policies and quality of implementation may be far from being
adequate (Humphreys, 2007). Thus regular monitoring or audit of the provision of TB IC
measures has been recommended. Examples of low compliance and inadequate implementation
were found in different countries, including hospitals in resource-rich settings: 122 Belgian
hospitals in 1995 were reported to isolate only 84% of patients suspected in infectious TB and to
have 96% of HCWs wearing masks, although masks were adequate in only 24% of rooms they
entered; UK hospitals with only 35% out of 144 surveyed, had more than one negative-pressure
rooms and only 27% had continuous automatic monitoring system of negative pressure of
isolation rooms. Study in several U.S. hospitals showed that day-to-day implementation of TB
IPC policy was not adequate with observed improper use of respirators by 65% of the HCWs and
lack of negative pressure in 19% of patient-rooms, suggesting need in regular monitoring of the
equipment’s performance (Sutton, Nicas, & Harrison, 2000).
17

Shenoi et al. (2010) have supported those recommendations pointing out existing gap in
information on effectiveness and implementation of TB IPC in resource-limited high HIV and
TB prevalence settings, and have indicated critical need to build such evidence (Shenoi et al.,
2010). More resources are needed for research and implementation of comprehensive airborne
IPC. Murphy (2008) has suggested that there is need in re-design of the current TB IPC protocols
in South Africa, even though the country made some progress in addressing MDR/XDR-TB
outbreaks, to prevent further spread of the epidemics to the neighboring countries that lack
resources and have high HIV prevalence (Murphy, 2008).

2.4. Summary of literature review
The literature acknowledges the main findings and recommendations made by WHO TB
IPC policy on the following points:


hierarchy of the TB infection controls by levels of effectiveness



substantial gaps in knowledge on efficacy and effectiveness of infection controls



urgent need in scale up of TB IC research and its inclusion as a critical component of
TB, HIV and overall infection control research agenda(WHO, 2009).

Importantly, the document has underscored that rapid implementation of TB IPC policy
based on the adequately estimated and allocated resources for all its elements would define its
success. In addition, monitoring of the implementation of TB IPC policies would need simple
indicators to measure progress.
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CHAPTER III: METHODS
This study employed a systematic review which refers to as “a review of the evidence on
a clearly formulated question that uses systematic and explicit methods to identify, select and
critically appraise relevant primary research, and to extract and analyze data from the studies that
are included in the review” (Higgins JPT, 2011). Biases in selection and assessing literature for
narrative or traditional literature reviews are not clear, thus might depend on the author’s agenda
and competence. Moreover, literature reviews are not replicable. Systematic review, in contrast,
identifies, assesses and synthesizes all available literature relevant to the defined question, uses
explicit methods, is open to external scrutiny, and can be replicated and updated. Importantly,
systematic review ensures a reliable basis for decision making.
The author started the systematic review process with defining a research question which
was “What is the current landscape of healthcare-related TB IPC research conducted in highprevalence settings among HCWs and patients on TB ICP policies and their implementation,
with a focus on preventing and controlling nosocomial transmission of MDR/XDR-TB?” (Table
2). A Protocol was developed with identification of inclusion and exclusion criteria (Table 3;
Annex1). Table 2. Research Question according to PICO
Population
MDR/XDR-TB
patients (all,
including PLHIV),
HCWs (all, including
PLHIV, excluding
laboratory)

Question/Intervention
TB infection
control measures ( as
defined by WHO TB
IC policy)

Outcome
Reduced
MDR/XDR-TB
incidence associated
with nosocomial
transmission

Setting
Healthcare
settings:
Any wards
(excluding
laboratory)
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Key search words were developed with the support of a librarian of the public health
school and then a search performed on two databases MEDLINE and EMBASE for published
research papers on TB IPC interventions in the period from 1 January, 1990 to 31 August, 2013,
based on a pre-established protocol (Table 3). The inclusion criteria was expanded to include
mathematical modeling studies that might present interest for this research because of the lack of
primary experimental human studies on TB infection control due to ethical issues. Only
publications reporting on primary studies that were peer reviewed and published in English were
included. Grey literature as well as case reports and qualitative studies were excluded from the
review. PUBMED database was first searched employing pre-set key search words that were
adapted then for EMBASE database search (Table 4). There was only one reviewer (the author)
who manually screened, identified and selected the publications based on the established criteria
from the list of titles with abstracts generated in the databases. Full texts were screened for the
relevant titles with missing abstracts. Duplicates were removed in two steps: first, establishing a
command for EMBASE database to exclude records from MEDLINE, which were already
covered by PUBMED; secondly, manually during the screening process.
Additionally, five relevant reviews were identified and their lists of references were
hand-searched to identify papers relevant to the research question and missing in the list of
selected papers from the databases. Results for both databases and snowballing of the reviews
are documented in a Flow Chart following the Cochrane standards (Figure 3) (Higgins JPT,
2011).
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Table 3. Selection Criteria for Papers
Inclusion Criteria



Exclusion Criteria

Full text papers reporting on human



Case reports

studies in any country



Qualitative studies

Title and abstract (or full text when



Grey literature

abstract is missing) in English;



Papers reporting equipment testing

publications in English


Papers reporting on mathematical

without human involvement


modeling

Papers related to laboratory infection
control



Papers not in English



Papers with full texts not found after
search efforts



Reviews

Data from all selected papers was extracted according to defined categories and entered
into MS Excel database (Microsoft Corp). Categories were defined and evaluated by the author
as levels of intervention (facility, administrative, environmental, personal), study design
(comparative, non-comparative), setting, population (HCWs, patients), sample size, geographic
location (WHO regional grouping applied), involvement of people living with HIV, and whether
the studies were conducted during or after outbreaks (Table 5). Income level of the countries
where the studies were conducted was included into categories to understand resources available
at settings. Additional analysis of the selected articles was conducted to identify publications
reporting on the same study and decide which papers were duplicate. This review did not intend
to make summary of the results of the selected studies, therefore no quality assessments and
meta-analysis were performed.
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Table 4. Search Terms by Database, Date, Period and Number of Hits
D
ate of
Search
8/28/2013

Resource
Used
(database, search
engine)
PubMed

Yea
rs Searched

Search Terms or Strategies
Used
(note Limits, MeSH, etc.)

# of
Hits/Result
s

1990-8/2013

("tuberculosis, multidrugresistant"[MeSH Terms] OR
("tuberculosis"[All Fields] AND
"multidrug-resistant"[All Fields]) OR
"multidrug-resistant tuberculosis"[All
Fields] OR ("drug"[All Fields] AND
"resistant"[All Fields] AND
"tuberculosis"[All Fields]) OR "drug
resistant tuberculosis"[All Fields]) AND
("Cross Infection/transmission"[Mesh]
OR "nosocomial transmission"[All
Fields]) AND ("1990/01/01"[PDAT] :
"2013/08/31"[PDAT])
(drug resistant tuberculosis) AND
"Infectious Disease Transmission,
Patient-to-Professional"[MeSH Terms]

119

8/28/2013

PubMed

1990-8/2013

58

8/28/2013

PubMed

1990-8/2013

("infection control"[MeSH Terms] OR
("infection"[All Fields] AND "control"[All
Fields]) OR "infection control"[All
Fields]) AND ("1990/01/01"[PDAT] :
"2013/08/31"[PDAT])

151

8/28/2013

PubMed

1990-8/2013

111

9/4/2013

EMBASE

1990-8/2013

(((drug resistant tuberculosis) AND
(("Cross Infection/transmission"[Mesh])
OR "nosocomial transmission"))) OR
((drug resistant tuberculosis) AND
"Infectious Disease Transmission,
Patient-to-Professional"[Mesh]) AND
infection control
'drug resistant tuberculosis'/exp
OR 'drug resistant tuberculosis'

9/4/2013

EMBASE

1990-8/2013

nosocomial AND ('infection'/exp
OR infection)

266
06

9/4/2013

EMBASE

1990-8/2013

'infection control'/exp OR 'infection
control'

944
15

9/4/2013

EMBASE

1990-8/2013

('drug resistant tuberculosis'/exp OR
'drug resistant tuberculosis') AND
(nosocomial AND ('infection'/exp OR
infection) OR ('infection control'/exp OR

204

413
8
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'infection control')) AND (('cross
infection'/exp OR 'cross
infection')OR('infection
transmission'/exp OR 'infection
transmission'))

Table 5. Categorization Criteria of Studies
Category
Study publication date

Description of Category
Studies were categorized as published during two periods of
time. First time period was defined as January 1990-December
2000. Second time period was defined as January 2001-August
2013.

Study setting

Studies were categorized according to the region and country
where the study was undertaken. Regions were defined
according to the WHO global grouping: European, African,
Region of Americas, Eastern Mediterranean, South-East Asia,
and Western Pacific. In addition, countries were defined
according to the WHO/World Bank criteria as low-income,
lower middle income, upper middle income, and high income.

Study design

Studies were categorized as comparative and noncomparative.
Comparative studies were defined as studies comparing casecontrol groups or pre-post intervention with or without
experimental design and randomization. Non-comparative
studies were defined as cross-sectional, descriptive, or
mathematical modelling studies that did not compare
interventions.

Study location

Study locations were categorized as routine setting, research
setting, or mixed routine/research settings. Research setting
was defined as setting with strong laboratory and clinical
research facilities; setting having routine clinical and laboratory
facilities was defined as routine; mixed setting included
combination of routine and mixed.
TB infection control measures involved in the studies were
categorized by levels according to the WHO TB IC Policy (see
Table 1): facility, administrative, environmental, and respiratory

TB infection control levels
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CHAPTER IV. RESULTS
There were 20 studies included for the analysis from 315 titles and abstracts screened
from the databases and additional sources (Figure 3; Table 5). Two hundred sixty five (265) titles
and abstracts were excluded after screening as not relevant to the research question (infection
control and nosocomial transmission of MDR/XDR-TB) and as not meeting pre-defined study
selection criteria. Twenty duplicate publications found as overlapping in two databases were
removed. Full texts of the rest 30 studies selected based on the title and abstract’s relevance to
the research question, were assessed for meeting eligibility criteria and 12 of them were excluded
as reporting on the same study (2), irrelevant content (9) as related more to establishing
nosocomial transmission of MDR-TB through genotyping, rather than looking into infection
control interventions, and having no target population (1). Additional search of relevant studies
which was performed by snowballing (handsearching) of the references of the selected five most
relevant literature reviews, resulted in two studies that were found relevant and eligible for
inclusion in analysis. In total, 20 studies were included in the systematic review.
The majority of them (65%) explored TB IC among both patients and HCWs, three
(15%) studied only patients and the remaining four (20%) only HCWs. Most the studies (70%)
were conducted in healthcare settings during or after a drug-resistant TB outbreak, and almost
the same proportion of the studies (75%) reported HIV infection in the populations of interest
(Table 5).
In terms of time, most of the studies (n=14) were published between 1992 and 2000, and
one third of them (n=6) from 2001 to 2012. Geographically, studies were undertaken
predominantly in the Americas region (12, 60%), Africa (4, 20%) and Europe (4, 20%). In the
Americas region eleven studies (92%) originated from the U.S., one (8%) from Canada; all
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studies (100%) in African region were from South Africa; reports from UK (25%), France
(25%), Spain (25%) and one study from EU&CIS countries (25%) comprised findings from the
European region (Figure 4). Seventy-five percent (n=15) of the studies were implemented in high
income and low prevalence of MDR/XDR-TB countries.
Sixteen studies (80%) addressed three and more TB IC levels of intervention; two studies
(10%) included only personal level, another one (5%) only administrative level and the last one
(5%) both facility and administrative levels. Proportion of investigations for each level of TB IC
didn’t vary substantially, showing personal and administrative levels reported each in 14 studies
(70%), environmental and facility levels in 12 (60%) and 13 (65%) studies respectively.
While one-third of the studies were implemented in the research settings (n=6), routine
setting was used by most of researchers (n=12). About half of the studies were comparative.
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Figure 3. Flow Chart for Selection of Studies on TB Infection Prevention and Control for
Nosocomial Transmission of MDR/XDR-TB, 1990 – 2013

Titles and abstracts screened from PUBMED: 111
Titles and abstracts screened from EMBASE: 204

# of duplicates excluded -20

#of irrelevant titles and abstracts:
PubMed- 87; EMBASE-178

# of full texts assessed for eligibility: 32
PubMed – 24; Embase – 6;
Identified from other sources (snowballing of
references of 5 reviews): 2
Number of full texts excluded: 12
Reporting on the same study-2
Irrelevant content – 9
No target population - 1

Number of full texts unavailable:
PubMed- 0; Embase - 0

Number of studies included in the systematic
review: 20
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Table 5. Studies Included in the Systematic Review
Citation
#

Title

(Farley
1
et al.,
2012)

A national infection control
evaluation of drug-resistant
tuberculosis hospitals in South
Africa.

Region/
Country

Study design
(comparative/
noncomparat)

African/South
Africa

noncomparative

Nosocomial tuberculosis
prevention measures among two
groups of US hospitals, 1992 to
1996.
(Dharmadhikari
3
et Surgical face masks worn by
al., 2012)
patients with multidrug-resistant
tuberculosis: impact on
infectivity of air on a hospital
ward.
(Basu
4
et al., 2007) Prevention of nosocomial
transmission of extensively
drug-resistant tuberculosis in
rural South African district
hospitals: an epidemiological
modelling study.
(Guerrero
5
et al.,
Nosocomial transmission of
1997)
Mycobacterium bovis resistant
to 11 drugs in people with
advanced HIV-1 infection.

1992-1996 Americas/US

comparative

2010

African/South
Africa

comparative

2007-2012 African/South
Africa

noncomparative

1993-1995 Europe/Spain

noncomparative

(Boudreau
6
et al.,
1997)

Occupational risk of
Mycobacterium tuberculosis
infection in hospital workers.

1989-1992 Americas/US

comparative

(Holton
7
et al.,
1997)

Comparison of tuberculosis
infection control programs in
Canadian hospitals categorized
by size and risk of exposure to
tuberculosis patients, 1989 to
1993 - Part 2
A nosocomial outbreak of
multidrug-resistant tuberculosis.

1989-1993 Americas/
Canada

noncomparative

1994-1995 Americas/US

noncomparative.

(Manangan
2
et al.,
2000)

(Kenyon
8
et al.,
1997)

Study year

2009
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(Jarvis,
9
1995)

1989-1992 Americas/US

comparative

1989-1992 Americas/US

comparative

(Stroud
1
et al.,
1995)

Evaluation of infection control
1989-1992 Americas/US
measures in preventing the
nosocomial transmission of
multidrug-resistant
Mycobacterium tuberculosis in a
New York City hospital.

comparative

(Wenger
2
et al.,
1995)

Control of nosocomial
transmission of multidrugresistant Mycobacterium
tuberculosis among healthcare
workers and HIV-infected
patients.
Efficacy of control
measures in preventing
nosocomial transmission of
multidrug-resistant tuberculosis
to patients and health care
workers.

1990-1992 Americas/US

comparative

1990-1992 Americas/US

comparative

The use of high-efficiency
particulate air-filter respirators
to protect hospital workers from
tuberculosis. A costeffectiveness analysis.
A nosocomial outbreak of
multidrug-resistant
Mycobacterium bovis among
HIV-infected patients. A casecontrol study.
Hospital outbreak of multidrugresistant Mycobacterium
tuberculosis infections. Factors
in transmission to staff and
HIV-infected patients.

1990-1992 Americas/US

noncomparative

1990-1993 Europe/France

noncomparative

1988-1990 Americas/US

comparative

(Ikeda
1
et al.,
1995)

(Maloney
1
et al.,
1995)

(Maloney
1
et al.,
1995)

(Bouvet
1
et al.,
1993)

(Beck-Sague
1
et
al., 1992)

Nosocomial transmission of
multidrug-resistant
Mycobacterium tuberculosis.
Nosocomial tuberculosis: an
outbreak of a strain resistant to
seven drugs.
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(Sotgiu
1
et al.,
2011)

TB and M/XDR-TB infection
control in European TB
reference centres: The Achilles'
heel?

(Basu
1
& Galvani,
2008)

The transmission and control of
XDR TB in South Africa: An
operations research and
mathematical modelling
approach

(Fella,
1
Rivera,
Hale, Squires, &
Sepkowitz, 1995)

Dramatic decrease in tuberculin
skin test conversion rate among
employees at a hospital in New
York City.
Investigation and control of a
large outbreak of multi-drug
resistant tuberculosis at a central
Lisbon hospital.

(Hannan
2
et al.,
2001)

2009-2010 Europe/EU
and CIS
countries
(intermediate
and low TB
incidence)
2006
African/South
Africa

noncomparative

1991-1993 Americas/US

comparative

1996-1997 Europe/UK

comparative

noncomparative
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Table 6. Results for Selected Studies

Appraisal

Year of publication
1990-2000
2001-2013
Region
European Region
African Region
Region of the Americas
Eastern Mediterranean Region
South-East Asia Region
Western Pacific Region
By Country
USA
Canada
South Africa
Spain
EU&CIS countries
France
UK
Study Design
Comparative
Non-comparative
TB IC by levels
Facility level
Administrative
Environmental
Personal

n=20

Country Income

MDR-TB
prevalence

high-income
high-income
middle-income
high-income
mixed-income
high-income
high-income

low-prevalence
low-prevalence
low-prevalence
low-prevalence
mix-prevalence
low-prevalence
low-prevalence

14 (70%)
6 (30%)

4 (20%)
4 (20%)
12 (60%)
0
0
0
11 (55%)
1 (5%)
4 (20%)
1 (5%)
1 (5%)
1 (5%)
1 (5%)
11 (55%)
9 (45%)
13
14
12
14
30

TB IC levels (<3 ) by study
TB IC levels (>3 ) by study
Personal
Facility &administr.
Administrative
Study location
Research setting
Routine setting
Mixed (research-routine) setting
Modelling (no setting)
Population
HCWs
Patients
Mixed
HIV infection
Outbreak of drug-resistant TB

16 (80%)
4 (20%)
2
1
1
6 (30%)
12 (60%)
1 (5%)
1 (5%)
4 (20%)
3 (15%)
13 (65%)
15 (75%)
14 (70%)
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CHAPTER V. DISCUSSION
Despite the large number of studies establishing nosocomial transmission of drugresistant TB among patients and HCWs and recommending improvement or introduction of TB
IPC measures, the results of this review show a paucity of published evidence on infection
control interventions to reduce or prevent nosocomial transmission of MDR/XDR-TB in highprevalence low-income settings. These findings might be of importance for the policy makers
on global, national and subnational levels, in the context of rapidly growing incidence of drugresistant TB in specifically above-mentioned areas with high TB and HIV burden and low
resources. Emerging drug-resistant TB epidemic signals on challenges and probably failures of
the current health systems in those countries either to develop and adequately implement
WHO’s TB ICP policies, or possibly adaptation of these policies to the local context. Factors
contributing to the nosocomial transmission of MDR/XDR-TB should be carefully investigated
to understand current gaps, barriers and challenges in developing and implementing TB ICP
policies.
The majority of the studies were undertaken during or after outbreaks in industrialized
countries and South Africa. Geographical concentration of studies in three regions and
countries with low prevalence and high or middle income and lack of studies in high burden
and low-income countries demonstrates an existing gap and critical need for further research in
the most affected regions. Although the highest burden of the drug-resistant TB is found in
developing countries and in certain regions (China, India, South Africa, Russian Federation,
Ukraine, Caucasus, Central Asia), there was only one study included in the review which was
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conducted in the European Union and CIS countries and might have covered low-income, high
prevalence country (WHO, 2013b). This raises questions on whether the findings are due to the
language and publication bias, and/or possible lack of expertise and resources. If the latter is
true there is a need for increase of awareness and political commitment of policy makers to
strengthening health systems including IPC policies and adequate practices along with the
capacity building and resource allocation for research.
The income level of countries seems to be related to how urgently and effectively
nosocomial drug-resistant TB has been addressed, as well as availability of resources for
research and development and implementation of infection control measures. For comparison,
the estimated percentage of MDR TB among cases in 2012 in some high-income countries
(e.g., United States) is 1% for new cases and 2.9 % for retreatment; in UK these values are
1.3% and 5.6% respectively; versus data from low-income high-burden countries such as
Armenia ( 9.4% and 43%), Somalia (5.2%, 41%) and Kyrgyzstan (26%, 68%) (WHO, 2013c).
Availability of in-country resources including technical expertise (CDC and research
centers/universities) and funding has been critical in responding to drug-resistant TB outbreaks.
Some studies following outbreaks in US showed that rigorous implementation of hierarchical
TB IPC measures recommended by CDC were effective to control outbreaks; however, they
require plentiful resources to implement those measures in a short period of time (Jensen,
Lambert, Iademarco, & Ridzon, 2005). Experience from South Africa shows the possibility of
collaboration with and attraction of expert teams to do research and establish evidence on
causes of and identification of interventions that have been effective in other countries.
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Guidelines were developed as a collaborative effort of WHO and CDC with focus on the
resource-limited settings (WHO/CDC, 1999).
The trend in publications over time demonstrates that the majority of studies have been
undertaken as a response to the outbreaks, highlighting a critical need in a systematic and
routine studies on TB IC of nosocomial transmission of drug-resistant TB in high-burden and
low-resourced areas. Similarly, regular monitoring and evaluation of implementation of TB IC
measures remains essential in low MDR/XDR-TB prevalence regions. In addition, a few
studies published in the recent years provide data on length of stay in the hospital, which has
been identified by WHO as one of the important recommendations on reduction of time spent
in the hospital as an administrative level measure to reduce risk of nosocomial transmission of
drug-resistant TB.
Most of the studies reported significant reduction of drug-resistant TB and skin test
conversions among HCWs after implementation of three and more levels of TB IC. This
confirms importance of comprehensive though hierarchical implementation of TB IC measures,
with the most effective and relatively less expensive administrative level, followed by
environmental and complimented by personal levels, as indicated in previous reviews (Nardell
& Dharmadhikari, 2010). Effectiveness of use of personal protection interventions alone
(respirators for HCWs, surgical masks for patients) varied across studies with some suggesting
their effectiveness, and others reporting high cost and low effectiveness.
Nosocomial transmission of drug-resistant TB to HCWs is indicated as a “special issue”
by majority of the studies, supporting this observation from one of the previous reviews, with
even higher skin test conversion rates (Shenoi et al., 2010). Some studies which compared
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TST results pre and post-intervention demonstrated significant reduction of conversion after
implementation of TB IPC measures. Other studies which compared risk of conversion of TST
of HCWs in wards with or without exposure to drug-resistant TB patients showed varying
results.
Studies suggest that in order to reduce nosocomial transmission of drug-resistant TB,
the priority and focus of TB IPC should be placed on adequate implementation of effective and
cost-effective measures, such as administrative (triage, isolation of infectious or suspected for
being infectious patients), adequate environmental, and respiratory (using masks) to ensure
protection of HCWs. Importantly, implementation of those policies should be stipulated by
context. Political commitment of the leadership on the national, subnational and facility levels
plays crucial role in resource allocation and proper implementation of TB IPC policies.
There is a need to implement, observe and learn about the effectiveness of TB IPC in
addressing nosocomial transmission of MDR/XDR-TB in low-income, high-burden settings
that are considerably different from high-income, low-burden settings where most research has
occurred. Where the resource context differs, it seems reasonable to expect practices to differ
also. As such, research in high-burden, low income countries could establish the effectiveness
or (lack thereof) of current TB IPC recommendations. It is possible that such research may
inform the establishment of new, context specific TB IPC and practice.
It is also concerning that less than one half of the 27 MDR-TB high-burden countries
(41%) reported having a national infection control plan (WHO, 2011). This suggests that an
important area for future research might be in identifying and understanding the underlying
reasons for this gap. Cross-sectional survey studies in conjunction with qualitative research cis
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needed to assess the factors that drive decision making in these countries, specifically focused
on why so many have neglected to implement IC policies. Another fact is that none of the
WHO reporting countries provided information on implementation of TB ICP policies,
including countries which report to have the policy in place. This highlights the need for further
research aimed at better understanding the policy implementation processes and dynamics, the
impact these policies have on practices, and the outcomes that are produced from the policies
and corresponding practice changes.
There is an opportunity for WHO and its technical group on infection control to
increase and prioritize its focus on these issues, both in terms of resources and time dedicated
to technical support to high burden, low income countries on development, implementation and
monitoring of TB IPC policies and strategies. Capacity building among these countries on IPC
policies and may contribute to the effective and consistent adoption and implementation of IC
practices with appropriate consideration of the local context (resources, culture, level of
awareness, stigma towards TB).
With globalization, health issues of some countries are no longer isolated. Further, they
cross national boundaries. In the case of drug-resistant TB epidemic, success to reduce or stop
its spread depends on the joint efforts of the global community. Efforts and resources should be
united to address the disease locally based on evidence that should be collected in the settings
with high TB burden, which are often low-resourced. More research on TB IPC and
nosocomial transmission of MDR/XDR-TB should be undertaken in these countries to guide
and inform locally feasible and effective policies and their implementation.
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5.1. Limitations
There were several limitations of this study. Only one person (an author) performed all
search and selection process that could result in selection bias. However, involvement of other
person or persons for independent selection and evaluation was not feasible, since this work
was done as a part of a graduate program thesis. There were two major databases searched
(PubMed, Embase), the study may benefit from more expanded search. Another limitation of
the review might be in a language bias, as only publications in English were included, that
excluded relevant articles published in other languages. Publication bias might lead to
availability of more studies with positive results of the interventions that tend to be submitted
and published rather than those with negative results. Also, because of the nature of the issue
considered, it was not possible to conduct rigorous selection of the studies (limited only to true
experimental studies on human subjects), which lack in this field due to ethics concern.

5.2. Conclusion
This systematic literature review showed a gap in research on TB IPC policies
addressing nosocomial transmission of MDR/XDR-TB in high-prevalence, low-income
settings. TB IPC policy development and implementation should be routinely undertaken as a
part of effective and efficient public health practice. TB IPC global best practices should be
reviewed and a concerted effort to promote, distribute, train, and implement these TB IPC
global best practices in low-resource countries would help mitigate the growing, global
incidence of MDR/XDR-TB.
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